ENDRA Life Sciences Inc. Overview
Pro stress-test →ENDRA Life Sciences is a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD). The company develops thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. This positions ENDRA at the intersection of hepatology, diagnostic imaging, and emerging precision health screening.
Strategic Profile
Pro stress-test →In May 2026, the company announced multi-site clinical validation results for its TAEUS® Liver device demonstrating strong agreement with MRI-PDFF, high reproducibility and consistent performance across operators, sites and patient populations. However, on March 25, 2026, the Board of Directors initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value, signaling potential inflection or structural challenges despite clinical progress.
Competitive Landscape
Pro stress-test →ENDRA competes in non-invasive liver disease diagnostics against established ultrasound vendors (GE, Siemens, Philips), emerging elastography platforms (FibroScan/Echosens), and advanced imaging modalities (MRI-based quantification). Barriers include entrenched clinical workflows, competitive technology portfolios from larger medtech firms, and payer coverage fragmentation for steatosis/fibrosis assessment.
Industry Context
ENDRA Life Sciences Inc. operates in Non-invasive hepatology diagnostics.
Key facts
Founded: Unknown · Headquarters: Ann Arbor, US · Employees: Unknown · Revenue: Estimated <$5M (pre-commercial stage) · Market cap: $6.81M (as of July 21, 2026)